Literature DB >> 23549097

Postoperative outcomes after fluocinolone acetonide implant surgery in patients with birdshot chorioretinitis and other types of posterior and panuveitis.

Bryn M Burkholder1, Jiangxia Wang, James P Dunn, Quan D Nguyen, Jennifer E Thorne.   

Abstract

PURPOSES: To evaluate outcomes after placement of fluocinolone acetonide (FA) implants in eyes with birdshot chorioretinitis and to compare these outcomes with eyes with posterior and panuveitis.
METHODS: This is a retrospective cohort study of 48 eyes from patients with posterior and panuveitis treated with FA implants from 2006 to 2010. Outcome measures include visual acuity, intraocular pressure, need for glaucoma surgery, postoperative complications, and control of inflammation.
RESULTS: All eyes treated with FA implants achieved improved control of inflammation and decreased reliance on adjunctive therapy. Birdshot chorioretinitis eyes had a statistically significant increase in intraocular pressure in the first 4 months after FA implantation (P = 0.04) compared with baseline intraocular pressure. A higher percentage of eyes with birdshot chorioretinitis required glaucoma surgery and after a shorter time period after FA implantation than did eyes with other forms of posterior and panuveitis (0.42/eye-year vs. 0.11/eye-year; median time to glaucoma surgery: 15.5 months vs. 31.5 months respectively, hazard ratio, 3.4; 95% confidence interval, 1.0-10.8, P = 0.04).
CONCLUSION: Although the FA implant is effective in controlling inflammation and reducing the need for systemic immunosuppressive therapy, eyes of patients with birdshot chorioretinitis tend to have a more robust intraocular pressure response to the FA implant than eyes with other types of posterior and panuveitis.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23549097      PMCID: PMC3828657          DOI: 10.1097/IAE.0b013e31828396cf

Source DB:  PubMed          Journal:  Retina        ISSN: 0275-004X            Impact factor:   4.256


  40 in total

1.  Fluocinolone acetonide sustained drug delivery device to treat severe uveitis.

Authors:  G J Jaffe; J Ben-Nun; H Guo; J P Dunn; P Ashton
Journal:  Ophthalmology       Date:  2000-11       Impact factor: 12.079

2.  A note on robust variance estimation for cluster-correlated data.

Authors:  R L Williams
Journal:  Biometrics       Date:  2000-06       Impact factor: 2.571

Review 3.  Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel.

Authors:  D A Jabs; J T Rosenbaum; C S Foster; G N Holland; G J Jaffe; J S Louie; R B Nussenblatt; E R Stiehm; H Tessler; R N Van Gelder; S M Whitcup; D Yocum
Journal:  Am J Ophthalmol       Date:  2000-10       Impact factor: 5.258

4.  Intraocular pressure response to topical corticosteroids.

Authors:  M F Armaly; B Becker
Journal:  Fed Proc       Date:  1965 Nov-Dec

5.  Birdshot retinochoroidopathy.

Authors:  S J Ryan; A E Maumenee
Journal:  Am J Ophthalmol       Date:  1980-01       Impact factor: 5.258

6.  Birdshot retinochoroiditis: long term follow-up of a chronically progressive disease.

Authors:  Kean T Oh; Nancy J Christmas; James C Folk
Journal:  Am J Ophthalmol       Date:  2002-05       Impact factor: 5.258

7.  A clinical evaluation of uveitis-associated secondary glaucoma.

Authors:  Tetsuya Takahashi; Shinichiro Ohtani; Kazunori Miyata; Norio Miyata; Shiroaki Shirato; Manabu Mochizuki
Journal:  Jpn J Ophthalmol       Date:  2002 Sep-Oct       Impact factor: 2.447

8.  Randomized comparison of systemic anti-inflammatory therapy versus fluocinolone acetonide implant for intermediate, posterior, and panuveitis: the multicenter uveitis steroid treatment trial.

Authors:  John H Kempen; Michael M Altaweel; Janet T Holbrook; Douglas A Jabs; Thomas A Louis; Elizabeth A Sugar; Jennifer E Thorne
Journal:  Ophthalmology       Date:  2011-08-15       Impact factor: 12.079

9.  Early rapid rise in intraocular pressure after intravitreal triamcinolone acetonide injection.

Authors:  Inder P Singh; Sameer I Ahmad; David Yeh; Pratap Challa; Leon W Herndon; R Rand Allingham; Paul P Lee
Journal:  Am J Ophthalmol       Date:  2004-08       Impact factor: 5.258

10.  Birdshot chorioretinopathy: long-term manifestations and visual prognosis.

Authors:  Aniki Rothova; Tos T J M Berendschot; Kiki Probst; Bram van Kooij; G Seerp Baarsma
Journal:  Ophthalmology       Date:  2004-05       Impact factor: 12.079

View more
  7 in total

1.  CHOROIDAL LESIONS UNRESPONSIVE TO FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT IN BIRDSHOT CHORIORETINOPATHY.

Authors:  Shuk Kei Cheng; Ian Thompson; Chinwenwa Okeagu; H Nida Sen
Journal:  Retin Cases Brief Rep       Date:  2022-01-01

Review 2.  Mechanisms, Pathophysiology and Current Immunomodulatory/Immunosuppressive Therapy of Non-Infectious and/or Immune-Mediated Choroiditis.

Authors:  Ioannis Papasavvas; Ilknur Tugal-Tutkun; Carl P Herbort
Journal:  Pharmaceuticals (Basel)       Date:  2022-03-24

Review 3.  Birdshot retinochoroidopathy.

Authors:  Albert T Vitale
Journal:  J Ophthalmic Vis Res       Date:  2014 Jul-Sep

Review 4.  Birdshot chorioretinopathy: current knowledge and new concepts in pathophysiology, diagnosis, monitoring and treatment.

Authors:  Evangelos Minos; Robert J Barry; Sue Southworth; Annie Folkard; Philip I Murray; Jay S Duker; Pearse A Keane; Alastair K Denniston
Journal:  Orphanet J Rare Dis       Date:  2016-05-12       Impact factor: 4.123

5.  Ozurdex for the Treatment of a Patient with Birdshot Chorioretinopathy.

Authors:  Elad Moisseiev; Ala Moshiri
Journal:  Case Rep Ophthalmol       Date:  2015-09-03

6.  Dexamethasone implantation in birdshot chorioretinopathy - long-term outcome.

Authors:  Asima Bajwa; Travis Peck; Ashvini K Reddy; Peter A Netland; Yevgeniy Shildkrot
Journal:  Int Med Case Rep J       Date:  2018-11-30

Review 7.  Birdshot uveitis: current and emerging treatment options.

Authors:  Victor Menezo; Simon Rj Taylor
Journal:  Clin Ophthalmol       Date:  2013-12-18
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.